Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
Bellomo, Rinaldo, Wunderink, Richard G, Szerlip, Harold, English, Shane W, Busse, Laurence W, Deane, Adam M, Khanna, Ashish K, McCurdy, Michael T, Ostermann, Marlies, Young, Paul J, Handisides, Damian R, Chawla, Lakhmir S, Tidmarsh, George F, Albertson, Timothy E
Published in Critical care (London, England) (06.02.2020)
Published in Critical care (London, England) (06.02.2020)
Get full text
Journal Article
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
Leisman, Daniel E., Handisides, Damian R., Chawla, Lakhmir S., Albertson, Timothy E., Busse, Laurence W., Boldt, David W., Deane, Adam M., Gong, Michelle N., Ham, Kealy R., Khanna, Ashish K., Ostermann, Marlies, McCurdy, Michael T., Thompson, B. Taylor, Tumlin, James S., Adams, Christopher D., Hodges, Tony N., Bellomo, Rinaldo
Published in Annals of intensive care (16.12.2023)
Published in Annals of intensive care (16.12.2023)
Get full text
Journal Article
ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock
Leisman, Daniel E, Handisides, Damian R, Busse, Laurence W, Chappell, Mark C, Chawla, Lakhmir S, Filbin, Michael R, Goldberg, Marcia B, Ham, Kealy R, Khanna, Ashish K, Ostermann, Marlies, McCurdy, Michael T, Adams, Christopher D, Hodges, Tony N, Bellomo, Rinaldo
Published in Critical care (London, England) (18.04.2024)
Published in Critical care (London, England) (18.04.2024)
Get full text
Journal Article
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Hu, Jinsong, Handisides, Damian R., Van Valckenborgh, Els, De Raeve, Hendrik, Menu, Eline, Vande Broek, Isabelle, Liu, Qian, Sun, Jessica D., Van Camp, Ben, Hart, Charles P., Vanderkerken, Karin
Published in Blood (02.09.2010)
Published in Blood (02.09.2010)
Get full text
Journal Article
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Laubach, Jacob P, Liu, Chia-Jen, Raje, Noopur S, Yee, Andrew J, Armand, Philippe, Schlossman, Robert L, Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H, Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T V, Dumke, Henry J, Chuma, Stacey, Savell, Alexandra, Handisides, Damian R, Kroll, Stew, Anderson, Kenneth C, Richardson, Paul G, Ghobrial, Irene M
Published in Clinical cancer research (15.01.2019)
Published in Clinical cancer research (15.01.2019)
Get full text
Journal Article
Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia
Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina
Published in American journal of hematology (01.08.2016)
Published in American journal of hematology (01.08.2016)
Get full text
Journal Article
A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Laubach, Jacob P., Liu, Chia-Jen, Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T.V., Dumke, Henry J., Chuma, Stacey, Savell, Alexandra, Handisides, Damian R., Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.
Published in Clinical cancer research (02.10.2018)
Published in Clinical cancer research (02.10.2018)
Get full text
Journal Article
Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302
Benito, Juliana M, Andrei, Volgin Y, Chen, Ye, Hongbo, Lu, Shi, Yuexi, McQueen, Teresa, Zweidler-McKay, Patrick A, Handisides, Damian R, Hart, Charles, Andreeff, Michael, Konopleva, Marina
Published in Blood (16.11.2012)
Published in Blood (16.11.2012)
Get full text
Journal Article
Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
Ghobrial, Irene M., Laubach, Jacob P., Raje, Noopur, Armand, Philippe, Schlossman, Robert L., Boswell, Erica N, Hanlon, Courtney, Chuma, Stacey, Handisides, Damian R, Kroll, Stewart, Anderson, Kenneth C., Richardson, Paul G.
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article
A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias
Konopleva, Marina, Handisides, Damian R, Richie, Mary Ann, Benito, Juliana M, Borthakur, Gautam, Jabbour, Elias J., Faderl, Stefan H., Cortes, Jorge E., Kroll, Stewart, Andreeff, Michael, Kantarjian, Hagop M, Thomas, Deborah A.
Published in Blood (15.11.2013)
Published in Blood (15.11.2013)
Get full text
Journal Article
Hypoxia Activated Prodrug TH-302 for the Treatment of Multiple Myeloma
Hu, Jinsong, Handisides, Damian R, Van Valckenborgh, Els, De Raeve, Hendrik, Menu, Eline, Broek, Isabelle Vande, Liu, Qian, Sun, Jessica D, Van Camp, Ben, Hart, Charles, Vanderkerken, Karin
Published in Blood (20.11.2009)
Published in Blood (20.11.2009)
Get full text
Journal Article